The neu oncogene was first identified as a transforming gene in ethylnitrosurea (ENU) induced rat neuroblastomas (Shih et al., 1981) . The human homologue was cloned by two independent groups and found to encode a product immunologically related to the epidermal growth factor receptor (EGFR) and named HER-2 (Coussens et al., 1985) or cerbB-2 (Semba et al., 1985) . The gene encodes a protein similar in structure to the EGFR with an external cellular transmembrane domain and an intracellular domain with tyrosine kinase activity. The extracellular ligand binding area is much smaller in c-erbB-2 than in EGFR, and the factor binding to this putative growth factor receptor is unknown. A candidate ligand for the c-erbB-2 receptor has recently been described in conditioned medium from rat cells transformed with the c-Ha-ras oncogene (Yarden & Weinberg, 1989) . However, this possible ligand has not yet been purified, nor has its gene been molecularly cloned, and therefore formally it is not known whether neu is indeed a growth factor receptor. In fact this has delayed the progress in understanding the biology of the frequent amplification of the c-erbB-2/neu gene in human breast carcinomas, some ovarian carcinomas and some other adenocarcinomas (Yokota et al., 1986 (Yokota et al., , 1988 Slamon et al., 1987 Slamon et al., , 1989 Venter et al., 1987 ; Van de Vijver et al., 1988a; Tavassoli et al., 1989; Wright et al., 1989) . Although Slamon et al. (1987) in an early report showed that the amplification was strongly correlated to early relapse and death from the disease, the subject is still a matter of controversies as other groups measuring gene amplification or protein over-expression found no correlation to poor prognosis (Ali et al., 1988; van de Vijver et al., 1988b) . The reason for these still contradictory findings could reflect various groups of patients with different genetic background, geographical location and nutritional or environmental factors.
The c-erbB-2 gene is located on chromosome 17q12-21.32 (Popescu et al., 1989) . Recently there has been a growing interest in the search for suppressor genes in breast cancers. Allele loss of chromosome 17 has been observed in a very high percentage of breast tumours (MacKay et al., 1988; Devilee et al., 1989) . The putative breast tumour suppressor gene on 17p may be the same as that already noted for colon and lung cancers, the p53 oncogene/antioncogene, and it has been suggested that deletion of this gene is one in a cumulative series of lesions involving genetic changes in the evolution of breast cancer.
The aim of this study has been to investigate the clinical and biological importance of c-erbB-2 oncogene amplification and loss of gene sequences on DNA analysis DNA was extracted from tissues using standard procedures (phenol/chloroform and EtOH precipitation) after mincing the tissue by a scalpel followed by digestion with proteinase K in 2% sarcosyl overnight at 4°C. Leucocyte DNA was isolated by the same method after lysis of the cells in 1% Triton X-100 followed by digestion with proteinase K in 0.5% SDS at 37°C overnight. Gene amplification of the DNA was analysed by Southern analysis after digestion with EcoRI. Hybridisation was performed using a 32P-labelled c-erbB-2 cDNA probe (Yamamoto et al., 1986) . Autoradiograms were developed at -70°C after 1-5 days. The degree of amplification in individual cases was determined by rehybridising the blots with a 32P-labelled CoOLA2 (Collagen I proa-2 chain) probe which is located on chromosome 7 (Myers et al., 1983) . All the autoradiograms were scanned using a Kontron IPS Densitometric Scanner, and the degree of amplification, adjusted for amount of DNA, was determined.
All the probes were radioactively labelled according to the random oligolabelling method (Feinberg & Vogelstein, 1983) .
Allele loss of chromosome 17 sequences in tumours was analysed by Southern analysis using two different VNTR probes, pYNZ22 (D17S30) and pRMU3 (D17S24), after digestion with the restriction enzyme TaqI. The localisation of the different probes used is shown in Figure 1 . Tumour and leucocyte DNA from the same patient was analysed on the same blot. The samples were scored for allele loss after the DNA loadings were judged by comparing the same blots with probes showing non-deleted alleles. If only a weak reduction of intensity of one allele band was seen, the autoradiograms were scanned by the laser scanning method described to obtain an objective measurement of the reduction. Immunostaining for c-erbB-2 protein Frozen sections from the breast carcinomas were immunostained applying a polyclonal antiserum raised in sheep (Cambridge Research Biochemicals). The c-erbB-2 protein antibody was raised against a 19 amino acid sequence from the intracytoplasmic domain of the human c-erbB-2 protein.
The avidin-biotin-peroxidase complex (ABC) method was used. The sections were treated with hydrogen peroxide to block endogenous peroxidase, incubated with normal serum to eliminate non-specific binding before incubation with specific antiserum (1:100 dilution) followed by sequential incubations with biotin labelled secondary antibody (1:200 dilution) and then avidin-biotin-peroxidase complex. The dilution of the primary antibody applied was titred out on paraffin blocks from a breast carcinoma known to be c-erbB-2 amplified. The peroxidase reaction was developed using diaminobenzidin as chromogen. Sections were counterstained with haematoxylin, dehydrated and mounted. The details of the procedure have previously been described (Nesland et al., 1989) . Positive and negative controls were performed as well as absorption controls of the primary antibody. The frozen sections were incubated with anti c-erbB-2 protein antiserum preabsorbed with c-erbB-2 protein as well as with EGFR (Cambridge Research Biochemicals) to exclude potential cross reactivity with EGFR. All controls gave satisfactory results.
Oestrogen (ER) and progesterone receptor (PgR) determinations ER and PgR were measured by standard dextran-coatedcharcoal method (DCC) method) in 29 of the primary tumours and nine of the metastases. In the remaining tumours ER and PgR were detemined by use of monoclonal antibodies in an enzyme immunoassay for quantitative measurement (Abbott ER and PgR-EIA monoclonal).
Statistical analysis
All comparisons between groups and or parameters were performed using Pearson's x2 analysis with Yates' correction. In comparisons where the total number was less than 50, Fisher's exact test was performed. P values < 0.05 were considered statistically significant.
Results
Results of a typical gene amplification and immunostaining analysis of c-erbB-2 are shown in Figure 2 and 3 respectively. In our material 20 of the 89 primary breast tumours (22.5%) had amplification of the c-erbB-2 gene, while 12 of the 24 metastases (50%) had amplification of the gene. This difference is highly significant (x2 = 7.05, P = 0.016). In one patient both the primary tumour and two metastases were examined. The primary tumour was amplified 5-10 times while the metastases were amplified 15-20 times.
The gene amplification correlated well with the protein over-expression (x2 = 50.3, P <0.0001) although five samples with gene amplification failed to show protein excess. The degree of gene amplification in these samples was moderate, approximately 2-5 gene copies. In one sample with a high degree of protein over-expression we did not find gene amplification. One of the explanations for this protein overexpression without gene amplification may be that this sample contains a mutation in the promotor region. Since our analysis is based on the effect of gene amplification, this sample was excluded from the further analysis. The immunostaining and gene amplification studies were done blindly.
The c-erbB-2 gene amplification in the primary breast tumours in relation to different clinical parameters is shown in Table I . A significantly higher proportion of gene amplification was found in oestrogen receptor negative tumours. The same difference was observed in the metastases. One out of nine (11 %) oestrogen receptor positive metastases had More than 50% (5/9) of the tumours with c-erbB-2 amplification also showed loss of 17q sequences. These findings Survival data of patients with primary breast tumours and with an observation time of more than 1 year were available for 51 patients. Early relapse or death in the c-erbB-2 amplified group was significantly increased compared to the nonamplified group (Table VI) . However, the numbers are too small, and the observation time too short to perform any multivariate analysis of these data. High expression of the c-erbB-2 oncogene has previously been reported to occur in a significant percentage of intraductal carcinomas (Van der Vijver et al., 1988b) . In our study c-erbB-2 amplification occurred in invasive ductal carcinomas. Only two cases of intraductal carcinomas were included, and none of them expressed c-erbB-2 amplification.
The c-erbB-2 gene encodes a putative growth factor receptor which shows extensive homology with the EGFR and may be involved in autocrine/paracrine growth regulation. The negative correlation to the ER and PgR and our previous finding that c-erbB-2 positive tumours have no production of hormones, suggest that there is no or little need for neuroendocrine differentiation in the c-erbB-2 positive tumour cells (Nesland et al., 1990) . Possibly, c-erbB-2 amplification may switch off the production of local hormones and receptors involved in growth modulation. Cells over-expressing the c-erbB-2 gene have also been found to have an increased resistance to tumour necrosis factor (Kartner & Lig, 1989 (Gaustad et al., 1990) . The positive correlation found between loss of retinoblastoma sequences and loss of 17p sequences (Gaustad et al., 1990) , indicate that several oncogenes and suppressor genes may be involved in the carcinogenesis of breast tumours. The inactivation of tumour suppressor genes and the activation of one or more oncogenes appear to be subsequent steps on the route towards malignancy in the breast. The sequence of these genetic events and the genetic characteristics of different tumour subtypes with characteristic biological features, is still unknown. Studies of different genetic alterations in larger series of tumours with known clinical outcome is needed. Studies of genetic alterations at different stages of the diseases may also reveal which alterations lead to a more malignant phenotype, and which alterations just reflect genetic instability. The different changes in oncogenes and tumour suppressor genes will hopefully be of use in the diagnosis and management of breast cancer.
